• Home
  • News
  • Calendar
  • About DF/HCC
  • Membership
  • Visitor Center

Maurizio Fava, MD


  • Ostergaard SD, Bech P, Trivedi MH, Wisniewski SR, Rush AJ, Fava M.Brief, unidimensional melancholia rating scales are highly sensitive to the effect of citalopram and may have biological validity: Implications for the Research Domain Criteria (RDoC).J Affect Disord. 2014 Jul;163:18-24.
  • Fava M, Ball S, Nelson JC, Sparks J, Konechnik T, Classi P, Dube S, Thase ME.Clinical relevance of fatigue as a residual symptom in major depressive disorder.Depress Anxiety. 2014 Mar;31(3):250-7.
  • Sarris J, Nierenberg AA, Schweitzer I, Alpert JE, Rosenbaum JF, Iovieno N, Covino J, Fava M, Mischoulon D.Conditional probability of response or nonresponse of placebo compared with antidepressants or St John's Wort in major depressive disorder.J Clin Psychopharmacol. 2013 Dec;33(6):827-30.
  • Jeon HJ, Peng D, Chua HC, Srisurapanont M, Fava M, Bae JN, Man Chang S, Hong JP.Melancholic features and hostility are associated with suicidality risk in Asian patients with major depressive disorder.J Affect Disord. 2013 Feb 12.
  • Papakostas GI, Vitolo OV, Ishak WW, Rapaport MH, Zajecka JM, Kinrys G, Mischoulon D, Lipkin SH, Hails KA, Abrams J, Ward SG, Meisner A, Schoenfeld DA, Shelton RC, Winokur A, Okasha MS, Bari MA, Fava M.A 12-week, randomized, double-blind, placebo-controlled, sequential parallel comparison trial of ziprasidone as monotherapy for major depressive disorder.J Clin Psychiatry. 2012 Dec;73(12):1541-7.
  • Farabaugh A, Alpert J, Wisniewski SR, Otto MW, Fava M, Baer L, Perlis R, Friedman E, Nyer M, Bitran S, Balasubramani GK, Inamori A, Trivedi M, Thase ME.Cognitive therapy for anxious depression in STAR(⁎)D: What have we learned?.J Affect Disord. 2012 Dec 15;142(1-3):213-8.
  • Gallagher PJ, Castro V, Fava M, Weilburg JB, Murphy SN, Gainer VS, Churchill SE, Kohane IS, Iosifescu DV, Smoller JW, Perlis RH.Antidepressant Response in Patients With Major Depression Exposed to NSAIDs: A Pharmacovigilance Study.Am J Psychiatry. 2012 Oct 1;169(10):1065-72.
  • Janes AC, Pizzagalli DA, Richardt S, Frederick Bde B, Holmes AJ, Sousa J, Fava M, Evins AE, Kaufman MJ.Neural substrates of attentional bias for smoking-related cues: an FMRI study.Neuropsychopharmacology. 2010 Nov;35(12):2339-45.
  • Kim BW, Kennedy DN, Lehár J, Lee MJ, Blood AJ, Lee S, Perlis RH, Smoller JW, Morris R, Fava M, Breiter HC, .Recurrent, robust and scalable patterns underlie human approach and avoidance.PLoS ONE. 2010;5(5):e10613.
  • Janes AC, Pizzagalli DA, Richardt S, Frederick BD, Chuzi S, Pachas G, Culhane MA, Holmes AJ, Fava M, Evins AE, Kaufman MJ.Brain Reactivity to Smoking Cues Prior to Smoking Cessation Predicts Ability to Maintain Tobacco Abstinence.Biol Psychiatry. 2010 Apr 15;67(8):722-9.
  • Davis LL, Wisniewski SR, Howland RH, Trivedi MH, Husain MM, Fava M, McGrath PJ, Balasubramani GK, Warden D, Rush AJ.Does comorbid substance use disorder impair recovery from major depression with SSRI treatment? An analysis of the STAR*D level one treatment outcomes.Drug Alcohol Depend. 2010 Mar 1;107(2-3):161-70.
  • Janes AC, Frederick B, Richardt S, Burbridge C, Merlo-Pich E, Renshaw PF, Evins AE, Fava M, Kaufman MJ.Brain fMRI reactivity to smoking-related images before and during extended smoking abstinence.Exp Clin Psychopharmacol. 2009 Dec;17(6):365-73.
  • Kashner TM, Trivedi MH, Wicker A, Fava M, Shores-Wilson K, Wisniewski SR, Rush AJ.Release bias in accessing medical records in clinical trials: a STAR*D report.Int J Methods Psychiatr Res. 2009 Sep;18(3):147-58.
  • Mischoulon D, Burger JK, Spillmann MK, Worthington JJ, Fava M, Alpert JE.Anemia and macrocytosis in the prediction of serum folate and vitamin B12 status, and treatment outcome in major depression.J Psychosom Res. 2000 Sep;49(3):183-7.
  • Fava M, Amsterdam JD, Deltito JA, Salzman C, Schwaller M, Dunner DL.A double-blind study of paroxetine, fluoxetine, and placebo in outpatients with major depression.Ann Clin Psychiatry. 1998 Dec;10(4):145-50.
  • Rosenbaum JF, Fava M, Hoog SL, Ascroft RC, Krebs WB.Selective serotonin reuptake inhibitor discontinuation syndrome: a randomized clinical trial.Biol Psychiatry. 1998 Jul 15;44(2):77-87.
  • Stewart JW, Quitkin FM, McGrath PJ, Amsterdam J, Fava M, Fawcett J, Reimherr F, Rosenbaum J, Beasley C, Roback P.Use of pattern analysis to predict differential relapse of remitted patients with major depression during 1 year of treatment with fluoxetine or placebo.Arch Gen Psychiatry. 1998 Apr;55(4):334-43.
  • Fava M, Mulroy R, Alpert J, Nierenberg AA, Rosenbaum JF.Emergence of adverse events following discontinuation of treatment with extended-release venlafaxine.Am J Psychiatry. 1997 Dec;154(12):1760-2.
  • Thase ME, Fava M, Halbreich U, Kocsis JH, Koran L, Davidson J, Rosenbaum J, Harrison W.A placebo-controlled, randomized clinical trial comparing sertraline and imipramine for the treatment of dysthymia.Arch Gen Psychiatry. 1996 Sep;53(9):777-84.
  • Fava M, Rappe SM, Pava JA, Nierenberg AA, Alpert JE, Rosenbaum JF.Relapse in patients on long-term fluoxetine treatment: response to increased fluoxetine dose.J Clin Psychiatry. 1995 Feb;56(2):52-5.
  • Rosenbaum JF, Fava M, Pava JA, McCarthy MK, Steingard RJ, Bouffides E.Anger attacks in unipolar depression, Part 2: Neuroendocrine correlates and changes following fluoxetine treatment.Am J Psychiatry. 1993 Aug;150(8):1164-8.
  • Fava M, Rosenbaum JF, Cohen L, Reiter S, McCarthy M, Steingard R, Clancy K.High-dose fluoxetine in the treatment of depressed patients not responsive to a standard dose of fluoxetine.J Affect Disord. 1992 Aug;25(4):229-34.
  • Fava M, Rosenbaum JF.Suicidality and fluoxetine: is there a relationship?.J Clin Psychiatry. 1991 Mar;52(3):108-11.
  • Rosenbaum JF, Fava M, Falk WE, Pollack MH, Cohen LS, Cohen BM, Zubenko GS.The antidepressant potential of oral S-adenosyl-l-methionine.Acta Psychiatr Scand. 1990 May;81(5):432-6.